{"name":"BioVaxys Technology","slug":"biovaxys","ticker":"BVXY","exchange":"CSE","domain":"biovaxys.com","description":"BioVaxys Technology is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company's lead product is its COVID-19 vaccine, which is currently in clinical trials. BioVaxys is also developing a SARS-CoV-2 vaccine for the prevention of COVID-19. The company's pipeline includes several other immunotherapies for various indications.","hq":"Vancouver, BC","founded":0,"employees":"","ceo":"James Baxter","sector":"Immuno-Oncology / Cell Therapy","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$12M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"BVX-0320 patent cliff ($0.00 at risk)","drug":"BVX-0320","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"regulatory","headline":"BioVaxys Announces FDA Clearance for COVID-19 Vaccine Clinical Trial","summary":"BioVaxys Technology announced that the US FDA has cleared its COVID-19 vaccine for a Phase 1 clinical trial.","drugName":"BVX-0320","sentiment":"positive"},{"date":"2023-11-01","type":"deal","headline":"BioVaxys Partners with University to Develop SARS-CoV-2 Vaccine","summary":"BioVaxys Technology has partnered with a university to develop a SARS-CoV-2 vaccine for the prevention of COVID-19.","drugName":"BVX-0320","sentiment":"positive"}],"realNews":[],"patents":[{"drugName":"BVX-0320","drugSlug":"covid-19-vaccine","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Moderna Therapeutics","BioNTech SE","Pfizer Inc."],"therapeuticFocus":["Immunotherapy","Oncology"],"financials":null,"yahoo":null}